Several mechanisms have been proposed to explain the observed synergism of trastuzumab and pertuzumab in treating HER2-positive cancers, including breast cancer, ovarian cancer, non-small cell lung cancer, and gastric cancer [178,179,180,181]. Here, ERBB2 is linked to ovarian cancer.